The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Nomination Committee appointed in respect of AGM 2023 in Intervacc
Stockholm, November 11, 2022 – According to the principles for the appointment of the Nomination Committee in Intervacc AB (publ) adopted at the annual general meeting held on June 14th, 2022, the Nomination Committee for the annual general meeting 2023 shall be...Interim report January – September 2022
The period in summary Third quarter July 1 – September 30, 2022 On July 20th, 2022 Intervacc announced that the company had received an order for the equivalent of approximately SEK 3 million from Dechra Pharmaceuticals PLC. The order concerns delivery of Strangvac®...Strangvac, a vaccine against equine strangles released for sales in Germany, France, Austria and the Benelux
Stockholm, October 12th, 2022 – Intervacc AB (publ) announces today that the first batch of Strangvac® for sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands has been released. “The first batch of Strangvac® for Germany, France, Austria,...Interim report January – June 2022
The period in summary First half year January 1 – June 30, 2022 On March 23 the first batch of Strangvac was released for sale in Sweden, and in the end of May we passed another milestone in the fight against strangles when Strangvac was released for sale in...Strangvac, a vaccine against equine strangles, is now available for sale in the UK
Stockholm, August 17th 2022 – Intervacc AB (publ) announces today that Strangvac® is now available for sale in the UK. This week Strangvac® has been launched in the UK and horse owners can now vaccinate their horses against the infectious equine disease...Nyhetstjänster
